Indian Journal of Radiology Indian Journal of Radiology  

   Login   | Users online: 492

Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size     

 

IMAGING IN ONCOLOGY: RECENT ADVANCES Table of Contents   
Year : 2015  |  Volume : 25  |  Issue : 2  |  Page : 102-108
Post-treatment imaging of high-grade gliomas


Department of Radiology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Darshana Sanghvi
Department of Radiology, Kokilaben Dhirubhai Ambani Hospital, 4 Bungalows, Andheri West, Mumbai - 400 053, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-3026.155829

Rights and Permissions

Current standard of care for treatment of newly diagnosed high grade gliomas is surgery followed by concomitant radiotherapy (RT) and chemotherapy (CT) with temozolomide (TMZ). Recently, bevacizumab, an anti - angiogenic agent has also been approved for treatment of recurrent gliomas. Baseline imaging after excision is optimally obtained in the first 24 hours. When baseline postoperative imaging is delayed beyond 24 hours, subacute hemorrhage, subacute ischemia and inflammation at the resection margins render differentiation from residual tumor challenging. Radiation necrosis is a well recognized entity and is differentiated from recurrence based on morphology on structural imaging, presence of lipid - lactate complexes with lack of choline on spectroscopy and low normalized cerebral blood volume (CBV) ratios at perfusion imaging. Novel chemotherapies have lead to the occurrence of interesting but sometimes confusing post treatment imaging appearances including the phenomena of 'pseudoprogression' and 'pseudoresponse'. Pseudoprogression refers to transient, self resolving focal enhancement mediated by TMZ-induced increased vascular permeability and local inflammatory response. Pathologically, these lesions do not have viable tumor. The lesions stabilize or regress without further treatment and are usually clinically asymptomatic. Pseudoresponse refers to rapid regression of enhancement, perfusion, mass effect and midline shift caused by the anti - angiogenic effect of bevacizumab. It is termed pseudoresponse since biological tumor persists as non-enhancing altered signal. It is important for radiologists to be aware of these entities seen on post treatment imaging of gliomas, as misinterpretation may lead to inappropriate management decisions and prognostication.


[FULL TEXT] [PDF]*
Print this article     Email this article

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
  Citation Manager
 Access Statistics
  Reader Comments
  Email Alert *
  Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed6058    
    Printed67    
    Emailed0    
    PDF Downloaded1023    
    Comments [Add]    

Recommend this journal